Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Key topics covered in this episode included:

* Criteria for adjuvant chemotherapy in early-stage TNBC

* The role of pembrolizumab in neoadjuvant and adjuvant settings

* Management of residual disease with capecitabine and olaparib

* Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02

* Side effect management strategies for new therapies

Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases!

Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment!

#TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan.

Key topics included:

• The role of PD-L1 positivity in treatment decisions

• Insights from the ASCENT-04 trial and its findings

• Common side effects associated with sacituzumab and strategies for management

• The future of immunotherapy and ADCs in TNBC treatment

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls. Don't forget to subscribe for more insightful discussions on cancer treatment!

#TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the evolving landscape of HER2-positive breast cancer treatment following the significant advancements made in 2025. Joined by Dr. Virginia Kaklamani from UT Health San Antonio, we discussed the latest data from SABCS 2025 and pivotal trials such as DESTINY-Breast09, which have led to new treatment approvals and strategies.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Key topics included:

• The treatment algorithm for early-stage HER2-positive breast cancer, including the APT trial and the role of trastuzumab.

• Insights into neoadjuvant and adjuvant therapies, including the implications of the neoCARHP trial regimen and the potential of T-DXd.

• The impact of recent studies in metastatic HER2-positive disease, including the approval of T-DXd plus pertuzumab and the promising results from the PATINA trial.

• A discussion on managing side effects and the importance of patient quality of life during treatment.

Join us for an informative conversation that highlights the latest advancements in HER2-positive breast cancer care and how they can be applied in clinical practice. Don't forget to like, subscribe, and leave a review to help us reach more healthcare professionals who can benefit from these discussions!

#HER2Positive, #BreastCancer, #SABCS25, #TDXd, #BreastCancerTreatment, #OncologyBrothers